AV

Alka Verma

Active Director Director DIN 11198458
DIN 11198458 First appointment Jul 2025 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2025
Shareholding value •••• Premium profile

About Alka Verma

Data last updated:

Alka Verma is a Director at Avizen Biopharma Private Limited (since 2025). The company operates in Pharma. Avizen Biopharma Private Limited reported revenue of ₹20.61 Cr (FY 2025).

DIN 11198458
Primary Designation Director
Industry Pharma
First Appointment 17 Jul 2025
Oldest Company Age 10 yrs
Largest company Avizen Biopharma Private Limited · ₹20.61 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Avizen Biopharma Private Limited U24304AS2016PTC017532
Director17 Jul 20252016₹20.61 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Avizen Biopharma Private Limited
Premium access

Shareholding and investment profile for Alka Verma

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Alka Verma

Alka Verma currently holds 1 directorship: Avizen Biopharma Private Limited (Director, since 17 Jul 2025, revenue ₹20.61 Cr (FY 2025)).

Alka Verma was first appointed on 17 Jul 2025 as Director at Avizen Biopharma Private Limited.

The current boards of Alka Verma's companies include Mahendra Kumar Verma (Avizen Biopharma Private Limited), Rajendra Kumar Verma (Avizen Biopharma Private Limited), Sunil Kumar Khemani (Avizen Biopharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available